425: Alumis to Merge with ACELYRIN, Creating Late-Stage Biopharma Focused on Immune-Mediated Diseases

Alumis and ACELYRIN have announced a merger agreement to create a well-capitalized, late-stage clinical biopharmaceutical company focused on developing and commercializing transformative therapies for immune-mediated diseases.

Summary

• Alumis and ACELYRIN have entered into a merger agreement, with Alumis acquiring ACELYRIN in an all-stock transaction.
• ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock owned.
• Post-merger, Alumis stockholders will own approximately 55% and ACELYRIN stockholders approximately 45% of the combined company.
• The combined company will have approximately $737 million in pro forma cash as of December 31, 2024, extending the cash runway into 2027.
• The merged entity will operate under the Alumis name and be led by the current Alumis executive team.
• The Alumis Board will expand to nine directors, including two additional directors from ACELYRIN's Board.
• The merger is expected to close in the second quarter of 2025, pending stockholder approvals and customary closing conditions.
• The combined company will focus on a differentiated pipeline with multiple upcoming milestones, including Phase 3 topline data for ESK-001 in psoriasis expected in 1Q 2026 and Phase 2b topline data for LUMUS trial in SLE expected in 2026.
• Alumis plans to initiate a Phase 2 clinical trial for A-005 in MS in 2025, with topline data expected in 2026.
• The company intends to invest approximately $25-50 million to evaluate the potential of lonigutamab in thyroid eye disease (TED).

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the merger, highlighting the potential benefits and synergies. While it acknowledges risks, the overall tone is optimistic and forward-looking.

Positives

• The merger creates a well-capitalized company with a strong cash position of approximately $737 million, extending the runway into 2027.
• The combined company has a late-stage clinical pipeline with multiple near-term catalysts, including Phase 3 data for ESK-001 and Phase 2b data for LUMUS.
• The merger brings together an experienced leadership team with a proven track record of operating discipline and capital efficiency.
• The combined company has a differentiated pipeline with three highly differentiated clinical programs (two TYK2 inhibitors and an IGF-1R inhibitor).
• Alumis' ESK-001 has shown promising clinical response rates in psoriasis trials.
• Alumis' A-005 is a potentially first-in-class, fully CNS-penetrant TYK2 inhibitor with opportunities in neuroinflammatory and neurodegenerative diseases.
• ACELYRIN's lonigutamab has best-in-class potential in thyroid eye disease (TED) with a uniquely differentiated MOA and compelling Phase 1/2 clinical data.

Negatives

• The merger is subject to stockholder approvals and customary closing conditions, which could delay or prevent the transaction from closing.
• The integration of ACELYRIN's operations and personnel may present challenges.
• The anticipated benefits and synergies of the merger may not be fully realized or may take longer to realize than expected.
• The company faces risks related to the development, commercialization, manufacturing, launching, marketing, and selling of potential existing and new products and product candidates.
• The company is subject to risks related to obtaining and maintaining regulatory approval for its product candidates.
• The company faces competition from other therapies and procedures that are rapidly growing and evolving.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• The required approvals of the proposed transaction, including stockholder approvals, may not be received.
• The announcement, pendency, or completion of the proposed transaction may negatively impact Alumis' or ACELYRIN's ability to attract, motivate, retain, and hire key personnel and maintain relationships with partners, suppliers, and others.
• The proposed transaction may divert management's attention from ongoing business operations.
• There is a risk of legal proceedings related to the proposed transaction.
• Alumis or ACELYRIN may be adversely affected by other economic, business, and/or competitive factors.
• Restrictions during the pendency of the proposed transaction may impact Alumis' or ACELYRIN's ability to pursue certain business opportunities or strategic transactions.
• The anticipated benefits and synergies of the proposed transaction may not be fully realized or may take longer to realize than expected.
• There are risks relating to the value of Alumis securities to be issued in the proposed transaction.
• Integration of the proposed transaction post-closing may not occur as anticipated, or the combined company may not be able to achieve the growth prospects expected from the transaction.
• The implementation of Alumis' and ACELYRIN's business model and strategic plans for product candidates and pipeline faces inherent challenges.
• The scope, progress, results, and costs of developing Alumis' and ACELYRIN's product candidates and any future product candidates are subject to risks.
• The timing and costs involved in obtaining and maintaining regulatory approval for Alumis' and ACELYRIN's current or future product candidates are subject to risks.
• The market for, adoption, pricing, and reimbursement of Alumis' and ACELYRIN's product candidates, if approved, are subject to uncertainties.
• Uncertainties exist in contractual relationships, including collaborations, partnerships, licensing, or other arrangements, and the performance of third-party suppliers and manufacturers.
• Alumis' and ACELYRIN's ability to establish and maintain intellectual property protection for products or avoid or defend claims of infringement is subject to risks.
• Alumis' ability to successfully integrate ACELYRIN's operations and personnel is subject to risks.
• Potential delays in initiating, enrolling, or completing preclinical studies and clinical trials exist.

Future Outlook

The combined company aims to innovate, develop, and commercialize transformative therapies for immune-mediated diseases, with multiple upcoming clinical milestones and a cash runway into 2027. They expect to evaluate lonigutamab's potential in TED with approximately $25-50M of committed capital.

Industry Context

The merger reflects a trend in the biopharmaceutical industry to consolidate assets and expertise to create larger, more competitive entities with diversified pipelines. The focus on immune-mediated diseases aligns with the growing market for therapies targeting these conditions.

Comparison to Industry Standards

• The document mentions SOTYKTU, OTEZLA, TREMFYA, HUMIRA, and SKYRIZI as existing treatments for psoriasis, indicating the competitive landscape.
• The document references GlobalData market research reports for market size estimates, suggesting an awareness of industry benchmarks.
• The document compares ESK-001 PASI 75 OLE response rates to those of other psoriasis studies, indicating an effort to benchmark performance against existing therapies.

Stakeholder Impact

• Shareholders of both Alumis and ACELYRIN will be impacted by the merger through changes in ownership and potential value creation.
• Employees of both companies may experience changes in roles and responsibilities as a result of the integration.
• Patients may benefit from the development of new and improved therapies for immune-mediated diseases.
• The merger may impact relationships with suppliers, partners, and other stakeholders.

Next Steps

• Obtain approval from Alumis and ACELYRIN stockholders.
• Satisfy other customary closing conditions.
• Finalize clinical development plan for lonigutamab.
• Initiate Phase 2 study in MS patients for A-005 in 2H25.
• Continue development of ESK-001 in psoriasis and SLE.

Key Dates